Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | SCN4A | P35499 | 1/20 | 0.52 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.49 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8237595 | 1.00 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1LMNANPSR1HSD17B10 | |
| SCHEMBL13114591 | 1.00 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1LMNANPSR1HSD17B10 | |
| SCHEMBL15746882 | 0.95 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1LMNANPSR1HSD17B10 | |
| SCHEMBL15746874 | 0.95 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1LMNANPSR1HSD17B10 | |
| SCHEMBL3554038 | 0.95 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1LMNANPSR1HSD17B10 | |
| SCHEMBL26430066 | 0.91 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1LMNANPSR1HSD17B10 | |
| SCHEMBL32691055 | 0.91 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1LMNANPSR1HSD17B10 | |
| SCHEMBL30419080 | 0.91 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1LMNANPSR1HSD17B10 | |
| SCHEMBL7422735 | 0.86 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1LMNANPSR1HSD17B10 | |
| SCHEMBL5403510 | 0.86 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1LMNANPSR1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419525-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2024-10-01 | — | — | US | disclosed |
| EP-4419525-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| CN-118556059-A | Heterocyclic compounds for the treatment of cancer | 阿提奥斯医药有限公司 | 2024-08-27 | — | — | CN | disclosed |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-08-22 | — | — | US | disclosed |
| WO-2023067353-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| EP-3331532-B1 | SUBSTITUTED AMINOQUINAZOLINE COMPOUNDS AS A2A ANTAGONIST | MERCK SHARP & DOHME LLC (US) | 2022-12-07 | — | — | EP | disclosed |
| US-20210371419-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-12-02 | — | — | US | disclosed |
| US-20150141401-A1 | NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857401-A1 | NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME | Meiji Seika Pharma Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
| US-8987297-B2 | Nitrogen containing compounds | WOCKHARDT LTD. (IN) | 2015-03-24 | — | — | US | disclosed |
| US-20150005285-A1 | Nitrogen containing compounds | WOCKHARDT LIMITED (IN) | 2015-01-01 | — | — | US | disclosed |
| US-8853197-B1 | Nitrogen containing compounds | WOCKHARDT LTD. (IN) | 2014-10-07 | — | — | US | disclosed |
| US-20140275018-A1 | NITROGEN CONTAINING COMPOUNDS | WOCKHARDT LIMITED (IN) | 2014-09-18 | — | — | US | disclosed |
| US-8822450-B2 | 1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections | WOCKHARDT LTD. (IN) | 2014-09-02 | — | — | US | disclosed |
| US-20140148431-A1 | 1,6- Diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections | WOCKHARDT LIMITED (IN) | 2014-05-29 | — | — | US | disclosed |
| WO-2013131018-A1 | BIARYL INHIBITORS OF THE SODIUM CHANNEL | ZALICUS PHARMACEUTICALS LTD. (US) | 2013-09-06 | — | — | WO | disclosed |
| WO-2012054510-A1 | OXADIAZOLE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | SMN1; SMN2 702/4885NPC1 903/4885LMNA 647/4885 |
| US-20150005285-A1 | Nitrogen containing compounds | NOS2, NOS1, NCF1 | SMN1; SMN2 2259/4885NPC1 1335/4885LMNA 2543/4885 |
| US-20140148431-A1 | 1,6- Diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections | ODC1, AOC1, CASP7 | SMN1; SMN2 2528/4885NPC1 560/4885LMNA 3159/4885 |
| US-20150141401-A1 | NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | ME1, FN1, FNTB | SMN1; SMN2 2493/4885NPC1 1651/4885LMNA 1112/4885 |
| US-20210371419-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | SMN1; SMN2 702/4885NPC1 903/4885LMNA 647/4885 |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | SMN1; SMN2 702/4885NPC1 903/4885LMNA 647/4885 |
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | SMN1; SMN2 702/4885NPC1 903/4885LMNA 647/4885 |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NQO1, VHL, SDHA | SMN1; SMN2 2654/4885NPC1 785/4885LMNA 851/4885 |
| US-20140275018-A1 | NITROGEN CONTAINING COMPOUNDS | NOS2, NOS1, NCF1 | SMN1; SMN2 2259/4885NPC1 1335/4885LMNA 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.